Palvella Therapeutics’ (PVLA) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $192.00 price objective on the stock.

A number of other brokerages also recently commented on PVLA. Cantor Fitzgerald upped their price objective on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. UBS Group reaffirmed a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Craig Hallum initiated coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial boosted their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $158.69.

Palvella Therapeutics Stock Down 4.1%

Shares of NASDAQ PVLA opened at $99.73 on Friday. The firm’s 50-day moving average price is $96.06 and its two-hundred day moving average price is $68.58. Palvella Therapeutics has a 52-week low of $12.10 and a 52-week high of $114.69. The stock has a market capitalization of $1.18 billion, a P/E ratio of -37.92 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, equities research analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Archer Investment Corp bought a new stake in Palvella Therapeutics in the third quarter worth about $28,000. Bank of America Corp DE increased its stake in shares of Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at about $36,000. JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after acquiring an additional 1,093 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics during the second quarter worth $37,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.